Onco Wiki / Regimen

Durvalumab consolidation post-CRT (NSCLC stage III unresectable)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-DURVALUMAB
IDREG-DURVA-CONSOLIDATION-PACIFIC
TypeRegimen
Statuspending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-NSCLC-EARLY-2024 SRC-NCCN-NSCLC-2025

Notes

PACIFIC: 5-year OS 43% (durva) vs 33% (placebo) post-concurrent CRT in stage III unresectable NSCLC. Standard of care.

Used By

Indication